Cargando…

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point in combating this virus was the development of a preventative vaccine composed of the HBV surface (envelope) prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Joan Kha-Tu, Jeevan-Raj, Beena, Netter, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077199/ https://www.ncbi.nlm.nih.gov/pubmed/31973017 http://dx.doi.org/10.3390/v12020126

Ejemplares similares

Subviral particle as vaccine and vaccine platform
por: Tan, Ming, et al.
Publicado: (2014)

Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
por: Gomez-Escobar, Elsa, et al.
Publicado: (2021)

An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine
por: Krauter, Steffi, et al.
Publicado: (2022)

A Recombinant Subviral Particle-Based Vaccine Protects Magpie (Pica pica) Against West Nile Virus Infection
por: Jiménez de Oya, Nereida, et al.
Publicado: (2019)

Subviral Agents
por: STRAUSS, JAMES H., et al.
Publicado: (2008)

Cryo-EM structures of human hepatitis B and woodchuck hepatitis virus small spherical subviral particles
por: Liu, Haitao, et al.
Publicado: (2022)

Activation of ERAD Pathway by Human Hepatitis B Virus Modulates Viral and Subviral Particle Production
por: Lazar, Catalin, et al.
Publicado: (2012)

Characterization Of The Interaction Between Subviral Particles Of Hepatitis B Virus And Dendritic Cells – In Vitro Study
por: Farag, Mohamed MS, et al.
Publicado: (2019)

Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?
por: Vaillant, Andrew
Publicado: (2022)

A Single Vaccination of IBDV Subviral Particles Generated by Kluyveromyces marxianus Efficiently Protects Chickens against Novel Variant and Classical IBDV Strains
por: Yang, Deqiang, et al.
Publicado: (2021)

Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus
por: Merino-Ramos, Teresa, et al.
Publicado: (2014)

Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine
por: Gogesch, Patricia, et al.
Publicado: (2019)

A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype
por: Eymieux, Sébastien, et al.
Publicado: (2022)

The Subviral RNA Database: a toolbox for viroids, the hepatitis delta virus and satellite RNAs research
por: Rocheleau, Lynda, et al.
Publicado: (2006)

The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy
por: Coppola, Nicola, et al.
Publicado: (2015)

Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles
por: Artpradit, Charlermchai, et al.
Publicado: (2013)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Development of a highly specific serodiagnostic ELISA for West Nile virus infection using subviral particles
por: Maezono, Keisuke, et al.
Publicado: (2021)

Virus-like Particle Vaccines and Platforms for Vaccine Development
por: Kheirvari, Milad, et al.
Publicado: (2023)

Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
por: Tabata, Koshiro, et al.
Publicado: (2023)

Dengue-specific subviral nanoparticles: design, creation and characterization
por: Khetarpal, Niyati, et al.
Publicado: (2013)

Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy
por: Scognamiglio, Paola, et al.
Publicado: (2009)

Protein Structure Predictions, Atomic Model Building, and Validation Using a Cryo-EM Density Map from Hepatitis B Virus Spherical Subviral Particle
por: DiNunno, Nadia, et al.
Publicado: (2023)

Virus like particles as a platform for cancer vaccine development
por: Ong, Hui Kian, et al.
Publicado: (2017)

The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles
por: Jiang, Bingfu, et al.
Publicado: (2020)

The Fittest versus the Flattest: Experimental Confirmation of the Quasispecies Effect with Subviral Pathogens
por: Codoñer, Francisco M, et al.
Publicado: (2006)

Analysis of a Common Cold Virus and Its Subviral Particles by Gas-Phase Electrophoretic Mobility Molecular Analysis and Native Mass Spectrometry
por: Weiss, Victor U., et al.
Publicado: (2015)

Hepatitis B core-based virus-like particles: A platform for vaccine development in plants
por: Moradi Vahdat, Maryam, et al.
Publicado: (2021)

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
por: Caldeira, Jerri C., et al.
Publicado: (2020)

Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins
por: Wang, Pei-Gang, et al.
Publicado: (2009)

Development of Chimeric Hepatitis B (HBV) – Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infection
por: Giri-Rachman, Ernawati Arifin, et al.
Publicado: (2023)

Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations
por: Mokaya, Jolynne, et al.
Publicado: (2021)

No evidence for occult HBV infection in hepatitis B vaccine non-responders
por: Aghasadeghi, Mohammad Reza, et al.
Publicado: (2014)

Virus-Like Particles, a Versatile Subunit Vaccine Platform
por: Donaldson, Braeden, et al.
Publicado: (2014)

Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture
por: Rajão, Daniela S., et al.
Publicado: (2018)

1051. Rapid onset of seroprotection rates in young adults immunized with a tri-antigenic hepatitis B virus (HBV) vaccine compared to a mono-antigenic HBV vaccine
por: Vesikari, Timo, et al.
Publicado: (2020)

Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus
por: Go, Hyeon-Jeong, et al.
Publicado: (2021)

Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China
por: Yang, Shigui, et al.
Publicado: (2015)

Seroconverting nonresponder of high-dose intramuscular HBV vaccine with intradermal HBV vaccine: A case report
por: Das, Manjusha, et al.
Publicado: (2017)

Subviral Dense Bodies of Human Cytomegalovirus Induce an Antiviral Type I Interferon Response
por: Penner, Inessa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9uqevmhnfvm79osrio1g1m2tf4